Intensive care risk and long-term outcomes in pediatric allogeneic hematopoietic cell transplant recipients.

"supplemental table 2 ). among demographic factors younger age lower median zip"

"Conflict of interest disclosure: A.S. has received consultant fee from Spotlight Therapeutics, Medexus Inc, Vertex Pharmaceuticals, Sangamo Therapeutics and Editas Medicine. He is a medical monitor for RCI BMT CSIDE clinical trial for which he receives financial compensation. He has also received research funding from CRISPR Therapeutics and honoraria from Vindico Medical Education. A.S. is the St. Jude Children’s Research Hospital–site principal investigator of clinical trials for genome editing of sickle cell disease sponsored by Vertex Pharmaceuticals/CRISPR Therapeutics (NCT03745287), Novartis Pharmaceuticals (NCT04443907) and Beam Therapeutics (NCT05456880). The industry sponsors provide funding for the clinical trial, which includes salary support paid to A.S.’s institution. A.S. has no direct financial interest in these therapies. G.G. is the Principal Investigator of Project Sickle Cure, a Sickle Cell Transplant Advocacy and Research Alliance (STAR) study partially funded by 10.13039/100016508bluebird bio. H.S. reports having received personal fees from Incyte, Janssen, Novartis, Sanofi and from the Belgian Hematological Society (BHS), as well as research grants from Novartis and the BHS, all paid to her institution and not related to this work. H.S. has also received nonfinancial support (travel grants) from Gilead, Pfizer, the European Society for Blood and Marrow Transplantation and the Center for International Bone Marrow Transplantation Research. M.S. served as a consultant and received honoraria from Jazz Pharmaceutical Canada. He received research funding from National Cancer Institute, PCORI, and Bluenote. C.C.D. reports consulting with Jazz Pharma and Alexion Inc. R.P. reports compensation from bluebird bio (advisory board) and Amgen (research funding; ended December 2021). K.M. reports significant payments: investigator initiated clinical trial sponsored by Incyte for early intervention for pulmonary dysfunction after stem cell transplant with ruxolitinib and industry sponsored clinical trial for ex vivo telomere elongation for patients with telomere biology disorders by Elixirgen Therapeutics and Proprietary Interests. K.M. has filed US provisional patent application #63/061,334, on 5 August 2021, entitled “Composition and Methods for the Treatment of Bronchiolitis Obliterans.” T.N. reports significant payments: research support to the institution for clinical trial (Novartis), research support (drug supply only) to the institution for clinical trial (Karyopharm) and relationships, advisory board membership (Medexus). The remaining authors report no competing financial interests."

"Funding for the study was provided by 10.13039/100000050National Heart, Lung, and Blood Institute (10.13039/100000050NHLBI; 10.13039/100000050NHLBI K23HL146936 (M.S.Z.). The Center for International Blood and Marrow Transplant Research is supported primarily by Public Health Service grant U24CA076518 from the 10.13039/100000054National Cancer Institute, the NHLBI, and the 10.13039/100000060National Institute of Allergy and Infectious Diseases; grant HHSH250201700006C from the 10.13039/100000102Health Resources and Services Administration; grants N00014-21-1-2954 and N00014-23-1-2057 from the 10.13039/100000006Office of Naval Research. Support was also provided by 10.13039/100001738Be The Match Foundation, the 10.13039/100008980Medical College of Wisconsin, the National Marrow Donor Program, and from the following commercial entities: 10.13039/100006483AbbVie; 10.13039/100010535Actinium Pharmaceuticals; Adaptimmune; 10.13039/100016796Adaptive Biotechnologies Corporation; ADC Therapeutics; Adienne SA; 10.13039/100024192Allogene; AlloVir, Inc; 10.13039/100002429Amgen; Angiocrine; Anthem; 10.13039/100004324Astellas Pharma US; 10.13039/100004325AstraZeneca; 10.13039/100016253Atara Biotherapeutics; 10.13039/100017239BeiGene; 10.13039/100016508bluebird bio; 10.13039/100002491Bristol Myers Squibb; 10.13039/100016477CareDx; CRISPR; 10.13039/100008322CSL Behring; 10.13039/501100022013CytoSen Therapeutics; Eurofins Viracor, DBA Eurofins Transplant Diagnostics; Gamida-Cell, Ltd; 10.13039/100005564Gilead; 10.13039/100004330GlaxoSmithKline; 10.13039/100006797HistoGenetics; 10.13039/100017655Incyte Corporation; Iovance; 10.13039/100005205Janssen Research & Development, LLC; Janssen/Johnson & Johnson; Jasper Therapeutics; 10.13039/100011096Jazz Pharmaceuticals; Kadmon; Karius; 10.13039/501100004072Kiadis Pharma; Kite, a Gilead company; 10.13039/100016348Kyowa Kirin; 10.13039/100019886Legend Biotech; Magenta Therapeutics; 10.13039/100014468Mallinckrodt Pharmaceuticals; Medexus Pharma; 10.13039/100004334Merck & Co; Mesoblast; Millennium, the Takeda Oncology Co; 10.13039/501100004176Miltenyi Biotec; 10.13039/501100013650MorphoSys; 10.13039/100008272Novartis Pharmaceuticals Corporation; 10.13039/100019510Omeros Corporation; OptumHealth; Orca Biosystems, Inc.; Ossium Health, Inc.; 10.13039/100004319Pfizer; Pharmacyclics, LLC, an AbbVie company; Pluristem; PPD Development, LP; 10.13039/100004339Sanofi; Sanofi-Aventis U.S. Inc; 10.13039/501100012112Sobi; 10.13039/100008761StemCyte; Takeda Pharmaceuticals; Talaris Therapeutics; Terumo Blood and Cell Technologies; 10.13039/100013252TG Therapeutics; 10.13039/100011022Vertex Pharmaceuticals; Vor Biopharma Inc; Xenikos BV."